Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome.

Eckhardt LL, Rajamani S, January CT.

Br J Pharmacol. 2005 May;145(1):3-4.

2.

hERG channel trafficking: novel targets in drug-induced long QT syndrome.

Dennis A, Wang L, Wan X, Ficker E.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1060-3. Review.

PMID:
17956279
3.

Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.

Witchel HJ, Hancox JC.

Clin Exp Pharmacol Physiol. 2000 Oct;27(10):753-66. Review.

PMID:
11022966
4.

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG.

Cardiovasc Res. 2003 Apr 1;58(1):32-45. Review.

5.
6.

Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.

Shah RR.

Novartis Found Symp. 2005;266:251-80; discussion 280-5. Review.

PMID:
16050273
7.
8.

The role of abnormal trafficking of KCNE1 in long QT syndrome 5.

Harmer SC, Tinker A.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1074-6. Review.

PMID:
17956282
9.

Mechanisms of drug induced QT interval prolongation.

Ponte ML, Keller GA, Di Girolamo G.

Curr Drug Saf. 2010 Jan;5(1):44-53. Review.

PMID:
20210718
10.

Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.

Abriel H, Schläpfer J, Keller DI, Gavillet B, Buclin T, Biollaz J, Stoller R, Kappenberger L.

Swiss Med Wkly. 2004 Nov 27;134(47-48):685-94. Review.

11.

Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2.

January CT, Gong Q, Zhou Z.

J Cardiovasc Electrophysiol. 2000 Dec;11(12):1413-8. Review.

PMID:
11196567
12.

[HERG K+ channel, the target of anti-arrhythmias drugs].

Guan FY, Yang SJ.

Yao Xue Xue Bao. 2007 Jul;42(7):687-91. Review. Chinese.

PMID:
17882949
13.

Molecular predictors of drug-induced prolongation of the QT interval.

Dilaveris PE.

Curr Med Chem Cardiovasc Hematol Agents. 2005 Apr;3(2):105-18. Review.

PMID:
15853698
14.
15.

I(Kr): the hERG channel.

Tseng GN.

J Mol Cell Cardiol. 2001 May;33(5):835-49. Review.

PMID:
11343409
16.

HERG channel trafficking.

Ficker E, Dennis A, Kuryshev Y, Wible BA, Brown AM.

Novartis Found Symp. 2005;266:57-69; discussion 70-4, 95-9. Review.

PMID:
16050262
17.

HERG block, QT liability and sudden cardiac death.

Brown AM.

Novartis Found Symp. 2005;266:118-31; discussion 131-5, 155-8. Review.

PMID:
16050265
18.

HERG trafficking and pharmacological rescue of LQTS-2 mutant channels.

Robertson GA, January CT.

Handb Exp Pharmacol. 2006;(171):349-55. Review.

PMID:
16610352
19.

[Molecular genetics of the long QT syndrome: clinical aspects].

Sepp R, Csanády M.

Orv Hetil. 1999 Nov 21;140(47):2633-8. Review. Hungarian.

PMID:
10613047
20.

Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia.

Sanguinetti MC.

Ann N Y Acad Sci. 1999 Apr 30;868:406-13. Review.

PMID:
10414310
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk